Recent advances in immunotherapy are reshaping the treatment landscape and improving outcomes for patients with resectable and advanced/metastatic melanoma. With many newly approved immunotherapy and combination approaches, a personalized approach to treatment selection and sequencing is crucial to optimize patient outcomes. Join our experts for an insightful discussion on integrating immunotherapies into melanoma care, including a review of the latest evidence, guideline recommendations, and multidisciplinary strategies to improve melanoma care in the federal, public, and government health settings.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/targeting-new-era-precision-oncology-treating-solid-tumors-federal-public
- Start Date: 2025-02-14 06:00:00
- End Date: 2025-02-14 06:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Aveo Pharmaceuticals - Amount: 2083.33 - Is Kind Support: False Source: Merck (Any division) - Amount: 16666.67 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest